U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,812.50
    -18.70 (-1.02%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.35%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.17%)
     
  • BTC-USD

    41,292.20
    +1,906.11 (+4.84%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

AbbVie, Caraway Therapeutics Team Up To Develop TMEM175 Modulators For Parkinson's Disease

·1 min read
  • Caraway Therapeutics has entered into an exclusive collaboration and option agreement with AbbVie Inc (NYSE: ABBV) to develop and commercialize Caraway's small molecule therapeutics targeting TMEM175.

  • Loss of function mutations in TMEM175 is associated with reduced lysosomal efficiency in a subpopulation of Parkinson's disease patients.

  • Under the terms of the agreement, Caraway will receive an upfront cash payment of $17 million.

  • After Caraway completes certain pre-clinical R&D activities for the collaboration program, AbbVie has an option to license the program and proceed into IND-enabling studies, clinical development, and commercialization.

  • Caraway is eligible to receive up to $267 million in payments, including upfront and future option payments and development milestones.

  • Caraway is a portfolio company of AbbVie Ventures.

  • Price Action: ABBV shares are down 0.12% at $112.21 in the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.